

Perimenopause, Menopause, and Presbyopia: Integrating Hormonal Transitions and Vision Changes in Midlife Women

A Comprehensive White Paper on Ocular Health and Quality of Life during Midlife Transitions

Meredith Bishop OD, MS, FAAO

Amber Gearhart

Perimenopause and menopause are significant milestones in a woman's life, marked by profound hormonal changes and a myriad of physiological shifts. Among these changes, vision disturbances are commonly reported and often underrecognized. This comprehensive white paper bridges foundational clinical evidence and emerging concepts, synthesizing two perspectives to provide healthcare providers and midlife women with actionable insights into the intersection of hormonal transitions and age-related vision changes.

Executive Summary

This integrated white paper examines the overlap between perimenopause, menopause, and presbyopia, exploring five key themes: (1) the role of hormonal transitions in accelerating near-vision symptoms, (2) eye dryness as a bridge symptom that compounds presbyopia, (3) the awareness gap in menopause-related eye changes, (4) the concept and management of 'ocular menopause,' and (5) opportunities to embed presbyopia education within menopause outreach. By reviewing underlying mechanisms, prevalence data, clinical evidence, and management strategies, this paper aims to guide both healthcare providers and women in navigating these interconnected changes.

Introduction

Women typically experience perimenopause in their 40s, leading toward menopause, defined as the cessation of menstruation for 12 consecutive months. This transition is characterized by fluctuating levels of estrogen and progesterone, with systemic effects that include ocular health.¹ Presbyopia—the age-related loss of near vision—also emerges during this period, raising important questions about the connection between hormonal changes and vision symptoms. While the mechanism for presbyopia is age-related loss of lens elasticity, hormonal fluctuations during menopause are highly associated with dry-eye and other ocular surface disturbances, which can intensify visual complaints.²

Understanding Perimenopause, Menopause, and Hormonal Effects

Perimenopause is the prelude to menopause and may last several years, with symptoms such as hot flashes, mood changes, sleep disturbances, and urogenital atrophy. Menopause marks the end of reproductive capability and is associated with sustained low estrogen levels. These hormonal shifts impact multiple organ systems, including the eyes. Declining estrogen and progesterone can alter metabolism, fluid balance, and the integrity of collagen and connective tissue, all of which may affect ocular structures.¹

Presbyopia: Age-Related Vision Change and Its Symptoms

Presbyopia is a gradual decline in the eye's ability to focus on near objects, typically becoming noticeable between ages 40 and 50. It is primarily attributed to decreased elasticity of the crystalline lens and weakening of the ciliary muscles. Symptoms include difficulty reading small print, eye strain, headaches during near work, and the need to hold reading material farther away. It is estimated that presbyopia affects over 1.8 billion people worldwide,³ with women often reporting symptoms earlier and more frequently than men.⁴

The Connection: Hormonal Transitions as Accelerators of Near-Vision Symptoms

While presbyopia is fundamentally an age-driven process, emerging evidence suggests that hormonal fluctuations during perimenopause and menopause can accelerate or intensify near-vision symptoms. Estrogen and progesterone receptors are present in the lens and other ocular structures, and declining levels may modulate lens oxidative stress, tear film stability, and overall ocular comfort.⁵ Clinical studies indicate that women may need a presbyopic add earlier and of greater magnitude than men, highlighting the potential role of the hormonal transition as an exacerbating factor rather than a primary cause.^{6,7}

Eye Dryness as a Bridge Symptom: Prevalence and Compounding Effects

Eye dryness emerges as a pivotal symptom linking hormonal changes to both ocular discomfort and the subjective experience of presbyopia. Its prevalence increases sharply during perimenopause and menopause, with higher rates of complaints such as fluctuating vision and blurred near tasks.⁸ Estrogen deficiency can reduce tear production and alter meibomian gland function, contributing to ocular surface instability. Eye dryness not only causes discomfort but also exacerbates visual blur and fatigue associated with presbyopia, compounding the impact on daily activities like reading and screen use.⁹

The Awareness Gap: Education and Evidence-Based Guidance

Despite the clinical significance of menopause-associated ocular changes, a substantial awareness gap exists among both patients and healthcare providers. Women may attribute vision changes solely to aging, overlooking the influence of hormonal transitions and the modifiable nature of symptoms. In addition to menopause symptoms on other parts of the body, impacts of vision changes to quality of life may include frustration, embarrassment during times of difficult vision, feeling older, and resignation to accepting the challenges of aging.¹⁰ *(alt: A survey of 500 US patients conducted by Johnson & Johnson, reported presbyopic vision changes impacted quality of life in a number of ways: from 45.8% being annoyed, to 43% being nervous to drive at night, and 36% feeling like it's another thing during this phase of life they can't control, and 30% feeling they are just too young for this to be happening. ¹⁰)* Menopause education may omit ocular health, and eye care guidance rarely addresses menopause-specific considerations, which can delay diagnosis and hinder optimal management. Healthcare systems should prioritize the dissemination of targeted, research-backed guidance on menopause-related eye changes.

Strategic Timing: Embedding Presbyopia Education in Menopause Platforms

The overlap in timing between the onset of presbyopia and menopause presents a strategic opportunity for education and intervention. Embedding presbyopia awareness and ocular health information within menopause-focused platforms—such as patient education materials, support groups, and digital health tools—may facilitate timely recognition of symptoms and encourage women to seek appropriate vision care. Coordinated outreach during this period maximizes the impact of health education and supports proactive management of both vision and systemic symptoms.¹⁰ *(option: A survey of 500 patients by Johnson & Johnson reports 94% of presbyopic patients are open to learning about vision needs at the same time as peri/menopause. ¹⁰)*

Integrated Management: The Concept of ‘Ocular Menopause’ and Practical Solutions

The convergence of presbyopia, hormonal changes, and eye dryness in midlife women supports the emerging framework of ‘ocular menopause’¹¹—a term encapsulating the unique constellation of vision and ocular surface symptoms in this demographic.

Integrated management approaches should include:

- Comprehensive health guidance for women approaching the age of 40 should emphasize the importance of annual eye examinations that include screening for presbyopia and dry eye. Equally significant are colonoscopy screenings, hormone management, mental health assessments, mammograms, dermatology evaluations, and related preventive measures.
- Women have a variety of resources to help maintain overall well-being during this stage of life, from hormone replacement, to healthy eating, weight bearing exercises and mindful approaches to the challenges of aging. Vision correction options can also be tailored to their lifestyle and goals. Personalized corrective lens options (progressive spectacles, reading glasses, multifocal contact lenses, contact lenses) tailored to symptom burden and lifestyle needs.
- Symptom connections:
 - Connecting the feeling of eye dryness to the dry and/or itchy skin associated with menopause provides a relevant connection.
 - Including Eye Dryness and Vision Changes in the top list of symptoms of menopause is an opportunity to drive connection and relevance
 - Evidence based dry eye therapies, such as prescription or OTC drops, in-office procedures, environmental modifications, and when appropriate discussion of hormonal therapy and its ocular implications.
- Awareness of lifestyle changes that support overall health as well as ocular surface health, like screen time management, nutrition, and hydration can be leveraged to drive relevance between the connection across need states.
- Collaborative care pathways linking primary care, gynecology, and ophthalmology/optometry for holistic support during menopause transitions.

Recognizing and addressing ‘ocular menopause’ as a clinical entity enables more effective, patient-centered care.

Conclusion

Perimenopause and menopause represent pivotal windows for the emergence and intensification of presbyopia and related ocular symptoms. Hormonal transitions may act as accelerators of near-vision complaints, with eye dryness serving as a bridge symptom that compounds the impact on quality of life. Closing the awareness gap and embracing integrated management—framed within the concept of ‘ocular menopause’—are essential for optimizing care. Embedding presbyopia education within menopause outreach initiatives offers a timely, effective strategy to support midlife women and healthcare providers in navigating these changes.

References

1. Ketch, C., Weedin, E., Gibson, B.A. (2023). Management of the Symptoms of Perimenopause. In: Shoupe, D. (eds) Handbook of Gynecology. Springer, Cham. https://doi.org/10.1007/978-3-031-14881-1_44
2. Peck T, Olsakovsky L, Aggarwal S. Dry Eye Syndrome in Menopause and Perimenopausal Age Group. J Midlife Health. 2017 Apr-Jun;8(2):51-54. doi: 10.4103/jmh.JMH_41_17. PMID: 28706404; PMCID: PMC5496280.
3. Fricke TR, Tahhan N, Resnikoff S, Papas E, Burnett A, Ho SM, Naduvilath T, Naidoo KS. Global Prevalence of Presbyopia and Vision Impairment from Uncorrected Presbyopia: Systematic Review, Meta-analysis, and Modelling. Ophthalmology. 2018 Oct;125(10):1492-1499. doi: 10.1016/j.ophtha.2018.04.013. Epub 2018 May 9. PMID: 29753495.
4. Hickenbotham A, Roorda A, Steinmaus C, Glasser A. Meta-analysis of sex differences in presbyopia. Invest Ophthalmol Vis Sci. 2012 May 31;53(6):3215-20. doi: 10.1167/iovs.12-9791. PMID: 22531698; PMCID: PMC3383187.
5. Nuzzi R, Caselgrandi P. Sex Hormones and Their Effects on Ocular Disorders and Pathophysiology: Current Aspects and Our Experience. Int J Mol Sci. 2022 Mar 17;23(6):3269. doi: 10.3390/ijms23063269. PMID: 35328690; PMCID: PMC8949880.
6. Pointer, J.S. (1995), The presbyopic add. II. Age-related trend and a gender difference. Ophthalmic and Physiological Optics, 15: 241-248. <https://doi.org/10.1046/j.1475-1313.1995.9400022r.x>
7. Patel I, West SK. Presbyopia: prevalence, impact, and interventions. Community Eye Health. 2007 Sep;20(63):40-1. PMID: 17971909; PMCID: PMC2040246.
8. Versura, P., Campos, E.C. (2007). Menopause and dry eye. Menopause International, 13(2), 79-85.

9. Gorimanipalli B, Khamar P, Sethu S, Shetty R. Hormones and dry eye disease. Indian J Ophthalmol. 2023 Apr;71(4):1276-1284. doi: 10.4103/IJO.IJO_2887_22. PMID: 37026259; PMCID: PMC10276676.
 10. US Multifocal Consumer Survey. N=500, 2025
 11. Agarwal S, Tackling Ocular Menopause: Presbyopia Management Strategies. Miophthalmology. April 1, 2023.
-

Important Safety Information: ACUVUE® Contact Lenses are indicated for vision correction. As with any contact lens, eye problems, including corneal ulcers, can develop. Some wearers may experience mild irritation, itching or discomfort. Lenses should not be prescribed if patients have any eye infection, or experience eye discomfort, excessive tearing, vision changes, redness or other eye problems. Consult the package insert for complete information. Complete information is also available from Johnson & Johnson Vision Care, Inc. by calling 1-800-843-2020, or by visiting www.jnjvisionpro.com.

All third-party trademarks herein are the intellectual property of their respective owners.

© Johnson & Johnson and its affiliates 2026

2026PP07145